Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 11·4 years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 12·7 and 8·5 years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12 years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.

OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind175
Udgave nummer3
Sider (fra-til)410-418
Antal sider9
ISSN0007-1048
DOI
StatusUdgivet - nov. 2016

ID: 49301883